期刊文献+

树突状细胞疫苗联合细胞因子诱导的杀伤细胞治疗用于预防结直肠癌术后复发转移的临床疗效观察 被引量:7

Clinical Effects of Immunotherapy with Dendritic Cell Vaccine and Ctokine-induced Killer Cells in Prevention of Recurrence and Metastasis for post-Surgery Colorectal Cancer Patients
暂未订购
导出
摘要 目的:评价树突状细胞(DC)疫苗联合细胞因子诱导的杀伤细胞(CIK)用于预防结直肠癌术后转移复发的临床疗效。方法:74例大肠癌术后患者分为两组,接受自体免疫细胞治疗设为I组(24例);未接受自体免疫细胞治疗为NI组(50例)。记录I组患者迟发型过敏皮肤测试(DTH)和发热反应情况,并对两组患者接受治疗前后生活质量、无病生存期(DFS)进行对比分析。结果:24例I组患者中,DTH阳性为12/24(50.00%),发热反应为15/24(62.50%);卡氏评分病人生存质量改善的在I组为8/24(33.33%),相比较于NI组(19/50,18.00%)显著提高(χ^2=7.063 P=0.029);Kaplan-Meier法生存期观察两组之间DFS,I组比NI组延长98 d(χ^2=4.304 P=0.038)结论:自体免疫细胞治疗早期结直肠癌,可以提高生存质量,延长复发时间。 ObjectiveTo evaluate the clinical effects of immunotherapy with dendritic cells(DC)and cyto-kine-induced Killer(CIK)cells on prevention of recurrence and metastasis in post-surgery patients with colorec-tal cancer(CRC).MethodsA total of 74 post-surgery patients with CRC were randomly divided into twogroups.24 cases who received immunotherapy with DC and CIK were defined as group I,50 cases who did notreceived the immunotherapy were defined as group NI.Delayed type hypersensitivity(DTH)skin test results andfever were abserved in Group I.Quality of life(QOL)and disease-free survival(DFS)were analyzed in bothgroups.ResultsPositive rates of DTH and fever were 12/24(50.00%)and 8/24(33.33%)respectively in groupI.Quality of life(QOL)by Karnofsky in group I was 8/24(33.33%)which was higher than that in group NI(19/50,18.00%,χ^2=7.063 P=0.029).DFS in group I(298 days)was longer than DFS in group NI(200 days,χ^2=4.304 P=0.038).ConclusionImmunotherapy with DC and CIK maybe improve QOL and prolong DFS inpost-surgery CRC.
出处 《中国中西医结合外科杂志》 CAS 2016年第2期112-116,共5页 Chinese Journal of Surgery of Integrated Traditional and Western Medicine
基金 天津市科技计划项目(12ZCDZSY17100)
关键词 结直肠癌 无病生存期 树突状细胞 细胞因子诱导杀伤细胞 Colorectal cancer disease-free survival dendritic cells cytokine-induced killer cells
  • 相关文献

参考文献13

二级参考文献323

共引文献226

同被引文献54

  • 1李增鹏,肖华亮,甘岫云,杜娟,王东.自体肿瘤疫苗治疗结直肠癌72例分析[J].消化外科,2006,5(5):390-390. 被引量:1
  • 2Zhang L, Yang X, Sun Z, et al.Dendritic cell vaccine and cyto?kine-induced killer cell therapy for the treatment of advancednon-small cell lung cancer[J]. Oncol Lett. 2016,11(4):2605-2610.
  • 3Zhu H, Yang X, Li J, et al. Immune response, safety, and survivaland quality of life outcomes for advanced colorectal cancer pa?tients treated with dendritic cell vaccine and cytokine-induced kill?er cell therapy[J]. Biomed Res Int,2014,2014:603871.doi:10.1155/2014/603871.
  • 4Cui Y, Yang X, Zhu W, et al. Immune response, clinical outcomeand safety of dendritic cell vaccine in combination with cyto?kine-induced killer cell therapy in cancer patients[J]. Oncol Lett,2013,6(2): 537-541.
  • 5Zhong R, Teng J. Dendritic cells combining with cytokine-inducedkiller cells synergize chemotherapy in patients with late-stagenon-small cell lung cancer[J]. Cancer Immunol Immunother Cii.2011, 60(10):1497-1502.
  • 6Niu J, Ren Y, Zhang T, et al. Retrospective comparative study ofthe effects of dendritic cell vaccine and cytokine-induced killercell immunotherapy with that of chemotherapy alone and in combi?nation for colorectal cancer[J].Biomed Res Int, 2014,2014:214727.doi:10.1155/2014/214727.
  • 7Liu J, Li J, Fan Y, et al. Concurrent dendritic cell vaccine andstrontium-89 radiation therapy in the management of multiplebone metastases[J]. Ir J Med Sci, 2014,184(2):457-461.
  • 8袁宏.128例临床输血不良反应分析[J].临床血液学杂志(输血与检验),2012,25(2):245-246. 被引量:15
  • 9王剑峰,孙旭,郭旭,徐孟,闫序波,赵德余.结肠癌复发转移相关因素的研究[J].中国实用医药,2012,7(36):84-86. 被引量:5
  • 10周莹,朱莹杰.大肠癌疗效及预后相关基因研究进展[J].肿瘤学杂志,2013,19(4):302-306. 被引量:4

引证文献7

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部